Frequency and Genetic Determinants of Tigecycline Resistance in Clinically Isolated in Beijing, China

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2018 Apr 11

PMID 29632524

Citations 17

Authors

Jin Zhao

Yunxi Liu

Yi Liu

Dong Wang

Wentao Ni

Rui Wang

Youning Liu

Bo Zhang

Affiliations

Soon will be listed here.

Abstract

is an emerging nosocomial pathogen with high resistance to most clinically used antimicrobials. Tigecycline is a potential alternative antimicrobial for infection treatment, but its resistance mechanism in clinical isolates is not fully elucidated. We investigated the antimicrobial susceptibility of 450 isolated during 2012-2015 from three university hospitals in Beijing, China. These strains exhibited high susceptibility to minocycline (98.44%), sulfamethoxazole/trimethoprim (87.56%), tigecycline (77.78 %), doxycycline (81.33%), levofloxacin (67.56%), and ticarcillin/clavulanate (73.00%). The susceptibility of tigecycline-nonsusceptible strains (TNS) to doxycycline and levofloxacin was much lower than that of tigecycline-susceptible strains (TSS) (25.00% vs. 97.71% for doxycycline, < 0.001; 17.00% vs. 82.00% for levofloxacin, < 0.001). We further selected 48 TNS and TSS and compared the detection rate of eight tetracycline-specific genes by PCR and the expression level of six intrinsic multidrug resistance efflux pumps by real-time PCR. Only one and two genes in TNS and three genes in TSS were detected, and the detection rate had no difference. The average expression level of in TNS was higher than that in TSS [20.59 (11.53, 112.54) vs. 2.07 (0.80, 4.96), < 0.001], while the average expression levels of , , , , and were not significantly different, indicating that was the predominant resistance genetic determinant in clinical . Higher expression was also observed in levofloxacin- and doxycycline-nonsusceptible isolates than in their corresponding susceptible isolates [16.46 (5.83, 102.24) vs. 2.72 (0.80, 6.25) for doxycycline, < 0.001; 19.69 (8.07, 115.10) vs. 3.01(1.00, 6.03), < 0.001], indicating that was also the resistance genetic determinant to levofloxacin and doxycycline. The consistent resistance profile and common resistance genetic determinant highlight the importance of rational use of tigecycline for preventing the occurrence and spread of multidrug resistance.

Citing Articles

Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.

Bostanghadiri N, Sholeh M, Navidifar T, Dadgar-Zankbar L, Elahi Z, van Belkum A Ann Clin Microbiol Antimicrob. 2024; 23(1):26.

PMID: 38504262 PMC: 10953290. DOI: 10.1186/s12941-024-00685-4.

complex: insights into evolutionary relationships, global distribution and pathogenicity.

Li K, Yu K, Huang Z, Liu X, Mei L, Ren X Front Cell Infect Microbiol. 2024; 13:1325379.

PMID: 38268792 PMC: 10806987. DOI: 10.3389/fcimb.2023.1325379.

Tetracycline-modifying enzyme SmTetX from Stenotrophomonas maltophilia.

Maly M, Kolenko P, Stransky J, Svecova L, Duskova J, Koval T Acta Crystallogr F Struct Biol Commun. 2023; 79(Pt 7):180-192.

PMID: 37405486 PMC: 10327574. DOI: 10.1107/S2053230X23005381.

Global prevalence and antibiotic resistance in clinical isolates of : a systematic review and meta-analysis.

Banar M, Sattari-Maraji A, Bayatinejad G, Ebrahimi E, Jabalameli L, Beigverdi R Front Med (Lausanne). 2023; 10:1163439.

PMID: 37215718 PMC: 10196134. DOI: 10.3389/fmed.2023.1163439.

Versatility of : Ecological roles of RND efflux pumps.

Chauviat A, Meyer T, Favre-Bonte S Heliyon. 2023; 9(4):e14639.

PMID: 37089375 PMC: 10113797. DOI: 10.1016/j.heliyon.2023.e14639.

References

Looney W, Narita M, Muhlemann K . Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009; 9(5):312-23. DOI: 10.1016/S1473-3099(09)70083-0. View

Bartha N, Soki J, Urban E, Nagy E . Investigation of the prevalence of tetQ, tetX and tetX1 genes in Bacteroides strains with elevated tigecycline minimum inhibitory concentrations. Int J Antimicrob Agents. 2011; 38(6):522-5. DOI: 10.1016/j.ijantimicag.2011.07.010. View

Sader H, Farrell D, Flamm R, Jones R . Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents. 2014; 43(4):328-34. DOI: 10.1016/j.ijantimicag.2014.01.007. View

Zhao J, Xing Y, Liu W, Ni W, Wei C, Wang R . Surveillance of Dihydropteroate Synthase Genes in by LAMP: Implications for Infection Control and Initial Therapy. Front Microbiol. 2016; 7:1723. PMC: 5080354. DOI: 10.3389/fmicb.2016.01723. View

Li X, Zhang L, Poole K . SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2002; 46(2):333-43. PMC: 127032. DOI: 10.1128/AAC.46.2.333-343.2002. View

Al-Hamad A, Upton M, Burnie J . Molecular cloning and characterization of SmrA, a novel ABC multidrug efflux pump from Stenotrophomonas maltophilia. J Antimicrob Chemother. 2009; 64(4):731-4. DOI: 10.1093/jac/dkp271. View

Li H, Wang X, Zhang Y, Zhao C, Chen H, Jiang S . The role of RND efflux pump and global regulators in tigecycline resistance in clinical Acinetobacter baumannii isolates. Future Microbiol. 2015; 10(3):337-46. DOI: 10.2217/fmb.15.7. View

Whitby P, Carter K, Burns J, Royall J, LiPuma J, Stull T . Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J Clin Microbiol. 2000; 38(12):4305-9. PMC: 87596. DOI: 10.1128/JCM.38.12.4305-4309.2000. View

Brooke J . Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012; 25(1):2-41. PMC: 3255966. DOI: 10.1128/CMR.00019-11. View

10.

He F, Fu Y, Chen Q, Ruan Z, Hua X, Zhou H . Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae. PLoS One. 2015; 10(3):e0119064. PMC: 4348519. DOI: 10.1371/journal.pone.0119064. View

11.

Garcia-Leon G, Hernandez A, Hernando-Amado S, Alavi P, Berg G, Luis Martinez J . A function of SmeDEF, the major quinolone resistance determinant of Stenotrophomonas maltophilia, is the colonization of plant roots. Appl Environ Microbiol. 2014; 80(15):4559-65. PMC: 4148791. DOI: 10.1128/AEM.01058-14. View

12.

Chen C, Huang C, Chung T, Hu R, Huang Y, Yang T . Contribution of resistance-nodulation-division efflux pump operon smeU1-V-W-U2-X to multidrug resistance of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2011; 55(12):5826-33. PMC: 3232770. DOI: 10.1128/AAC.00317-11. View

13.

Stein G, Babinchak T . Tigecycline: an update. Diagn Microbiol Infect Dis. 2013; 75(4):331-6. DOI: 10.1016/j.diagmicrobio.2012.12.004. View

14.

Gould V, Avison M . SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships. J Antimicrob Chemother. 2006; 57(6):1070-6. DOI: 10.1093/jac/dkl106. View

15.

Walkty A, Adam H, Baxter M, Denisuik A, Lagace-Wiens P, Karlowsky J . In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob Agents Chemother. 2014; 58(5):2554-63. PMC: 3993217. DOI: 10.1128/AAC.02744-13. View

16.

Sader H, Flamm R, Jones R . Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagn Microbiol Infect Dis. 2013; 76(2):217-21. DOI: 10.1016/j.diagmicrobio.2013.02.009. View

17.

Fluit A, Schmitz F, Verhoef J . Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur J Clin Microbiol Infect Dis. 2001; 20(3):188-91. DOI: 10.1007/s100960100455. View

18.

Sharma V, Johnson N, Cizmas L, McDonald T, Kim H . A review of the influence of treatment strategies on antibiotic resistant bacteria and antibiotic resistance genes. Chemosphere. 2016; 150:702-714. DOI: 10.1016/j.chemosphere.2015.12.084. View

19.

Tekce Y, Erbay A, Cabadak H, Sen S . Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother. 2012; 24(3):150-4. DOI: 10.1179/1120009X12Z.00000000022. View

20.

Hu L, Chang X, Ye Y, Wang Z, Shao Y, Shi W . Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents. 2011; 37(3):230-4. DOI: 10.1016/j.ijantimicag.2010.10.025. View